SCHEMBL21708014

SCHEMBL21708014

Cc1ccc(-c2cn3cc(F)ccc3n2)cc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A3 P47895 5/20 0.82
NPC1 O15118 8/20 0.74
RAB9A P51151 7/20 0.74
SMN1; SMN2 Q16637 5/20 0.74
ALDH1A1 P00352 5/20 0.74
KDM4E B2RXH2 3/20 0.74
PAX8 Q06710 2/20 0.74
KMT2A Q03164 2/20 0.74
MEN1 O00255 1/20 0.74
MITF O75030 1/20 0.74
KDM5A P29375 1/20 0.74
KDM5C P41229 1/20 0.74
APP P05067 3/20 0.72
CYP11B1 P15538 3/20 0.66
CYP11B2 P19099 3/20 0.66
SLC2A1 P11166 1/20 0.64
TP53 P04637 2/20 0.58
PKM P14618 2/20 0.58
HPGD P15428 1/20 0.58
TSHR P16473 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22906630 0.91 APP (0.73) ALDH1A3NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL1691890 0.90 ALDH1A3 (0.82) ALDH1A3NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL396368 0.85 NPC1 (1.00) ALDH1A3NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL2258357 0.85 NPC1 (0.66) ALDH1A3NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL1983592 0.85 APP (0.66) ALDH1A3NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL1691421 0.85 NPC1 (0.75) ALDH1A3NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL29438982 0.84 ALDH1A3 (0.79) ALDH1A3NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL21727398 0.84 APP (0.65) ALDH1A3NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL12380446 0.84 ALDH1A3 (0.75) ALDH1A3NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL13325772 0.84 ALDH1A3 (0.87) ALDH1A3NPC1RAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US claimed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP claimed
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US disclosed
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US disclosed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP disclosed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine DOT1L, NSD1, KDM3A ALDH1A3 111/4885NPC1 4209/4885RAB9A 3350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.